10-Q: Calidi Biotherapeutics Q2 Loss Narrows Amid Liquidity Concerns

Calidi Biotherapeutics reported a reduced net loss for the first half of 2025, driven by lower administrative costs, but faces ongoing liquidity challenges and a going concern warning.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $10.8 million, compared to $13.0 million for the same period in 2024.
• Research and development expenses increased by $0.1 million (2%) to $5.0 million for the six months ended June 30, 2025, primarily due to higher consulting and rent expenses.
• General and administrative expenses decreased by $1.9 million (25%) to $5.7 million for the six months ended June 30, 2025, mainly due to reductions in legal fees, salaries, benefits, and insurance.
• Cash balance stood at $5.3 million as of June 30, 2025, a decrease from $9.6 million at December 31, 2024.
• Net cash used in operating activities increased to $12.0 million for the six months ended June 30, 2025, from $9.3 million in the prior year period.
• The company had an accumulated deficit of $132.4 million as of June 30, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within 12 months from the date of issuance of the financial statements.
• The company completed a 1-for-10 reverse stock split on July 15, 2024, and a 1-for-12 reverse stock split on August 4, 2025, with all share and per share amounts retrospectively restated.
• CLD-201, a SuperNova investigational drug candidate, received Fast Track Designation from the U.S. FDA in July 2025 for soft tissue sarcoma.

Sentiment

Score: 3

Explanation: While the company achieved a Fast Track Designation and reduced its net loss, the explicit 'going concern' warning, accelerating cash burn from operations, and declining cash balance indicate severe financial distress and high reliance on dilutive capital raises, outweighing the clinical progress.

Positives

• Net loss decreased by 17% to $10.8 million for the six months ended June 30, 2025, compared to $13.0 million in the prior year period.
• General and administrative expenses significantly decreased by 25% ($1.9 million) for the six months ended June 30, 2025, reflecting cost optimization efforts.
• CLD-201, a SuperNova investigational drug candidate, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in July 2025 for the treatment of patients with soft tissue sarcoma, potentially accelerating its development and review.
• Successfully raised $6.6 million from public offerings and $3.5 million from a Registered Direct Offering and Concurrent Private Placement during the first half of 2025.
• Reduced total liabilities to $7.3 million at June 30, 2025, from $12.2 million at December 31, 2024, largely due to repayment of term notes and bridge loans.

Negatives

• The company continues to experience recurring losses from operations and negative cash flows from operating activities, with an accumulated deficit of $132.4 million as of June 30, 2025.
• Net cash used in operating activities increased to $12.0 million for the six months ended June 30, 2025, from $9.3 million in the prior year, indicating an accelerating cash burn.
• Cash balance declined to $5.3 million at June 30, 2025, from $9.6 million at December 31, 2024, highlighting a deteriorating liquidity position.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within 12 months from the financial statement issuance date.
• The company's ability to continue as a going concern is dependent on raising additional funding, which may not be secured in a timely manner or on favorable terms, if at all.
• Issuance of equity securities to raise funds will likely result in further dilution for existing stockholders.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and negative cash flows.
• Dependence on securing significant additional capital through public or private equity/debt financing or collaboration agreements, which may not be available on favorable terms or at all.
• Potential for significant dilution to existing stockholders if additional equity securities are issued.
• Product candidates are subject to long development cycles, with no guarantee of successful preclinical studies, clinical trials, or regulatory approval.
• Uncertainty regarding the timing and ability to realize significant revenue from product sales, if ever.
• Reliance on key personnel and the ability to attract and retain qualified employees.
• Challenges in protecting proprietary technology and intellectual property.
• Compliance with extensive government regulations in the biotechnology industry.
• Impacts of changes in economic conditions, including rising interest rates, volatile equity capital markets, and geopolitical conflicts.
• Ongoing legal proceedings, including a lawsuit from a former Chief Accounting Officer seeking $0.6 million in damages and punitive damages, and a securities fraud complaint, with uncertain outcomes.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses as it advances product candidates through preclinical and clinical development, seeks regulatory approval, and expands its intellectual property portfolio. Substantial additional funding will be required to support continuing operations and growth strategy, likely through public or private equity offerings, debt financings, or collaboration agreements. The RedTail platform's first compound, CLD-401, is expected to commence a Phase I trial by the end of 2026.

Management Comments

• Management expects operating losses and negative cash flows to continue for the foreseeable future.
• Management's ability to continue as a going concern is dependent upon its ability to raise additional funding.
• The company believes it does not have sufficient cash on hand to support current operations for at least one year from the date of issuance of the unaudited condensed consolidated financial statements.
• The elimination of the President, Medical and Scientific Affairs position is part of the company's ongoing review of its organizational structure and cost optimization efforts.

Industry Context

Calidi Biotherapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology industry, focusing on genetic medicines and oncolytic viruses for cancer therapy. The industry is characterized by long development cycles, high regulatory hurdles, and significant R&D investment. The company's approach of protecting oncolytic viruses from immune clearance and delivering genetic payloads directly to tumors addresses a major challenge in the field, as evidenced by the limited success of previous oncolytic virus therapies like T-VEC, which is restricted to local delivery. The Fast Track Designation for CLD-201 highlights the potential unmet medical need in soft tissue sarcoma, aligning with broader industry trends towards targeted and innovative cancer treatments.

Comparison to Industry Standards

• As a clinical-stage biotechnology company, Calidi Biotherapeutics' recurring losses and negative cash flows are typical for companies in this development phase, as significant capital is required for research, preclinical studies, and clinical trials before any product revenue can be generated.
• The company's accumulated deficit of $132.4 million is common for biotech firms that have not yet commercialized products, reflecting substantial historical investment in R&D and intellectual property.
• The reliance on equity and debt financings, including 'At The Market' offerings and warrant inducements, is a standard capital-raising strategy for early-stage biotech companies, though the frequency and dilutive nature of these raises can be more pronounced for companies facing significant liquidity challenges.
• The explicit 'going concern' warning indicates a more severe liquidity position compared to many peers who might have a longer cash runway or more diversified funding sources, placing it in a higher risk category within the industry.
• The Fast Track Designation for CLD-201 is a positive development, comparable to similar designations received by other biotech companies for promising drug candidates, which can expedite regulatory review and potentially bring the product to market faster than standard pathways.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit filed by former Chief Accounting Officer and interim Chief Financial Officer, Tony Kalajian, alleging defamation and constructive discharge, seeking $0.6 million in damages, punitive damages, and attorneys' fees. The company denies allegations and has filed counterclaims.
• Lawsuit filed against a former executive assistant alleging breach of fiduciary duty and misappropriation of confidential information, seeking injunctive relief and damages.
• Securities matter filed by Mr. Yian Zeng alleging securities fraud, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud. The company denies all claims.

Related Party Transactions

• Related party term notes payable to Directors A and E totaling $0.8 million as of June 30, 2025, down from $2.7 million at December 31, 2024.
• Amounts owed to Director F and a relative of Officer A for reimbursable expenses and legal fees, totaling $21,000 as of June 30, 2025.
• Obligation to pay Director F (former CEO Mr. Camaisa) $500,000 separation pay over 12 months and COBRA premiums for 12 months, plus $10,000 per month transition/consulting pay.
• Settlement of severance accrual and accrued interest for former President and COO George K. Ng in January 2025.
• Settlement of accrued advisory fees for Director A (Scott Leftwich) in January 2025.
• Payment due to Director F for a personal Guaranty of Lease, with a present value of approximately $4,000 as of June 30, 2025.
• Settlement of $0.6 million in deferred compensation and accrued interest due to Mr. Leftwich in January 2025.
• Nova Cell, a subsidiary, received a strategic investment of approximately $2.0 million from a related-party accredited investor for 25% of Nova Cell's fully-diluted capitalization.

Stakeholder Impact

• Shareholders face significant dilution from ongoing and future equity capital raises due to the company's substantial funding requirements and going concern warning.
• Employees may experience organizational restructuring, as evidenced by the elimination of an executive position, potentially impacting morale and job security.
• Creditors are exposed to the risk associated with the company's 'going concern' uncertainty, although some debt obligations have been reduced.
• Patients and the medical community could benefit from the continued development of the company's oncolytic virus platforms, particularly with the Fast Track Designation for CLD-201, if successful.

Next Steps

• Advance current and future product candidates through preclinical and clinical development.
• Manufacture drug product and drug supply for clinical trials.
• Seek regulatory approval for current and future product candidates.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Operate as a public company, incurring associated costs.
• Commence a Phase I trial for CLD-401 (RedTail platform) by the end of 2026.
• Enter into a Separation and General Release of Claims Agreement with Dr. Boris Minev.

Key Dates

Recommendation

The company faces severe liquidity challenges, explicitly stating 'substantial doubt about its ability to continue as a going concern.' While net losses decreased and a Fast Track Designation was received, the accelerating cash burn from operations and continuous reliance on highly dilutive equity raises pose significant risks to existing shareholders. The stock is highly speculative, and the financial instability outweighs the early-stage clinical progress for a seasoned investor.

Keywords

Biotechnology, Oncolytic Virus, Cancer Therapy, Genetic Medicine, Clinical Stage, Oncology, SEC Filing, 10-Q, Biopharma, Drug Development, Going Concern, Reverse Stock Split, Fast Track Designation